The US Department of Health and Human Services (HHS) has released final guidance for the second cycle of Medicare drug price negotiations.
Aiming to further lower prescription drug costs, the talks will take part under the mandate provided by the Inflation Reduction Act.
The first set of price reductions, announced in August, is projected to save Medicare recipients $1.5 billion in out-of-pocket costs in 2026. The guidance also confirms that up to 15 more drugs will be selected for negotiation by February 2025, with those new prices taking effect in 2027.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze